Actively Recruiting
Risk of Anemia and Effects of Oral Iron Therapy in Non-Anemic Iron-Deficient Women (18-55 Years)
Led by Istanbul University - Cerrahpasa · Updated on 2025-12-04
60
Participants Needed
1
Research Sites
25 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study investigates the risk of anemia development in women aged 18-55 years with non-anemic iron deficiency and evaluates the clinical effects of oral iron therapy. The study consists of a two-month nutritional intervention phase followed by a one-month oral iron treatment phase. Participants first receive dietary counseling aimed at increasing iron intake and absorption. After two months, changes in hematologic parameters and symptoms are evaluated. Women with persistent iron deficiency then receive daily oral ferrous sulfate (80 mg elemental iron) for one month. The study aims to identify early predictors of anemia progression and to assess the impact of dietary modification and oral iron therapy on symptoms and laboratory findings.
CONDITIONS
Official Title
Risk of Anemia and Effects of Oral Iron Therapy in Non-Anemic Iron-Deficient Women (18-55 Years)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female participants aged 18-55 years (including premenopausal and menopausal women)
- Normal hemoglobin level (≥ 12 g/dL)
- Serum ferritin < 15 µg/L (WHO criteria for iron deficiency)
- Mentzer index > 13
- Normal vitamin B12, folic acid, thyroid hormones (TSH and sT4), and C-reactive protein (CRP < 5 mg/L) levels
- Non-anemic iron deficiency confirmed by laboratory results
- Good general health and ability to provide informed consent
- Willingness to participate, comply with study procedures, and provide written informed consent
You will not qualify if you...
- Pregnancy or postpartum period
- Acute or chronic infections
- History or suspicion of malignancy
- Chronic inflammatory or autoimmune diseases
- Chronic fatigue syndrome or depressive disorders
- Chronic kidney disease or renal failure (acute or chronic)
- Congestive heart failure, ischemic heart disease, or cerebrovascular disease
- Coagulopathy or significant bleeding tendency
- Hematological disorders (e.g., thalassemia, hemoglobinopathies)
- Postoperative patients, transplant recipients, or dialysis patients
- Currently using any form of iron supplementation or treatment
- Any condition interfering with safety or study result interpretation as judged by investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Kagıthane No. 5 Family Health Center
Kâğıthane, Istanbul, Turkey (Türkiye), 34413
Actively Recruiting
Research Team
O
Osman Demir, MD
CONTACT
A
Ayşen Fenercioğlu, Assoc Prof
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here